TickerFactsScreenerDevelopers

Spyre Therapeutics, Inc. (SYRE) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2016: -$18.84M2017: -$24.61M2018: -$32.19M2019: -$65.69M2020: -$75.78M2021: -$53.72M2022: -$80.14M2023: -$99.91M2024: -$157.41M2025: -$169.25M-$169.25M
2016Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$169.25M-7.5%
2024-$157.41M-57.6%
2023-$99.91M-24.7%
2022-$80.14M-49.2%
2021-$53.72M+29.1%
2020-$75.78M-15.3%
2019-$65.69M-104.1%
2018-$32.19M-30.8%
2017-$24.61M-30.7%
2016-$18.84M—